Acme United Q2 2026 Earnings Beat Driven by MyMedic Acquisition and Margin Recovery

• Acme United reported Q2 2026 earnings significantly exceeding analyst expectations, with EPS reaching $1.22 against a forecast of $0.81.
• Revenue surged 16% year-over-year to $62.7 million, driven by the MyMedic acquisition and 8% organic growth in the core business.
• Management anticipates continued margin expansion as tariff-related cost pressures subside and lower-cost inventory replaces higher-tariff stock.

Acme United Corporation (ACU) delivered robust second-quarter 2026 results, significantly outperforming market expectations. Earnings per share reached $1.22, beating analyst estimates of $0.81, while revenue hit $62.7 million versus a forecasted $58.1 million . The stock surged approximately 11.92% following the report, reaching near its 52-week high .

The primary driver of this outperformance was the acquisition of MyMedic, which contributed to a 16% year-over-year sales increase . Excluding acquisition effects, organic growth stood at 8% . Gross margins expanded to 42.6% from 41.0% in the prior year period, indicating improved operational efficiency .

CEO Johnsen highlighted that margin recovery is expected to continue through the end of the year as the company transitions from higher-tariff inventory to lower-cost stock . This strategic inventory management is critical for mitigating recent tariff impacts . The MyMedic integration remains a key focus, with plans to expand distribution beyond direct-to-consumer channels into mass retail .

What Factors Are Driving Acme United's Margin Recovery?

Acme United exhibits distinct financial characteristics that differentiate it from its industry peers. The company’s Asset Turnover TTM stands at 1.139, more than double the industry average of 0.538, indicating significantly higher efficiency in generating revenue from its asset base. Similarly, the Current Ratio of 3.23 suggests strong short-term liquidity, well above the industry norm of 2.33 .

For the period ending June 30, 2026, Acme United reported explosive growth in key income statement metrics, signaling a strong operational recovery or margin expansion. EBITDA surged by 136.78% to $8.801 million, accompanied by a corresponding increase in EBIT to $6.83 million . The EBITDA margin improved to 14.03%, reflecting enhanced operational efficiency or favorable pricing dynamics .

Most notably, both Basic and Diluted EPS from continuing operations grew by over 400% (411.18% and 408.33% respectively), reaching $1.32 and $1.22 . This dramatic EPS growth was driven by operational improvements rather than share count changes, as weighted average shares remained stable around 3.82 to 4.14 million .

What Are the Key Risks Facing Acme United Investors?

Despite these positive developments, investors should monitor key risks, including elevated selling, general, and administrative (SG&A) expenses at 32% of sales . Additional headwinds include potential tariff and freight cost fluctuations, currency volatility, and uneven geographic performance, particularly with the Canadian market lagging behind other regions .

Acme United has a documented history of quarterly dividend payments, showing a gradual upward trend in absolute payout amounts over the last four years . Between 2022 and 2026, the quarterly dividend increased from $0.13 to $0.16 per share . However, the dividend yield has trended downward over the period, starting at approximately 2.55% in early 2023 and settling around 1.32% by mid-2026 .

The company’s Beta of 0.49 indicates lower volatility than the broader market (industry beta 0.85), appealing to conservative investors . Additionally, while the 5-year average dividend yield is 1.12%, slightly below the industry's 1.44%, the recent dividend growth rate of 6.67% shows a commitment to returning capital, even if the absolute yield remains modest .

Looking forward, the company is focusing on integrating MyMedic beyond its direct-to-consumer channel into mass retail . Strong Q4 profitability is anticipated due to seasonal demand for medical devices . Investors should note that such high growth rates may reflect a low-base effect from a previous downturn, making sustainability a key area for further analysis .